Question

A Merck representative visits your office and tells you that Fosamax® (alendronate) will decrease the incidence of repeat hip fracture by 50% over 3 years. That excites you because you have 20 elderly women and 5 elderly men who already have fractured one hip in your practice. You locate the study by Black in Lancet (1996) and find out that fracture occurs in 2.2% of placebo patients and 1.1% of patients on alendronate (Fosamax®).

What is the EER in this example?

Answer 1

not that sure but through referring few studies I have come to conclusion

EER in this example should be you find out that fracture occurs in 2.2% of placebo patients & 1.1.% of patients on alendronate.